Video
Dr. Sophia Kamran discusses bladder-preservation therapy
“We call it ‘trimodality therapy,’ because it involves the 3 main disciplines: surgery, radiation oncology, and medical oncology,” says Kamran.
Video Player is loading.
Sophia Kamran, MD, discusses the background and clinical evidence supporting the use of bladder-preservation, or “trimodality,” therapy for patients with bladder cancer. Kamran is a radiation oncologist at Massachusetts General Hospital and assistant professor of Radiation Oncology at Harvard Medical School.
Related Videos
Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
Expert describes implications of neoadjuvant durvalumab approval in MIBC
Sima Porten, MD, on gene-environment interactions in bladder cancer development
How rBCG EAP could open up access for Anktiva in bladder cancer
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
Joshua J. Meeks, MD, PhD, discusses the impact of neoadjuvant durvalumab approval in MIBC
Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
Related Content
